1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional,
and national cancer incidence, mortality, years of life lost, years
lived with disability, and disability-adjusted life-years for 29 cancer
groups, 1990 to 2016: a systematic analysis for the global burden of
disease study. JAMA Oncol. 2018;4:1553-1568.
2. Rustgi A, El-Serag HB. Esophageal carcinoma. N Engl J Med.
2015;372:1472-1473.
3. Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam
Physician. 2017;95:22-28.
4. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell
carcinoma refractory or intolerant to previous chemotherapy
(ATTRACTION-3): a multicentre, randomised, open-label, phase 3
trial. Lancet Oncol. 2019;20:1506-1517.
5. Kojima T, Shah MA, Muro K, et al. Randomized phase III
KEYNOTE-181 study of pembrolizumab versus chemotherapy in
advanced esophageal cancer. J Clin Oncol. 2020;38:4138–4148.
6. Moynihan KD, Irvine DJ. Roles for innate immunity in combination
immunotherapies. Cancer Res. 2017;77:5215-5221.
7. Jalil AR, Andrechak JC, Discher DE. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-
SIRPalpha structure-function. Antib Ther. 2020;3:80-94.
8. Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends
Cell Biol. 2009;19:72-8 0.
9. Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and
therapeutic target. Annu Rev Immunol. 2014;32:25-50.
10. Murata Y, Saito Y, Kotani T, Matozaki T. Blockade of CD47 or
SIRPalpha: a new cancer immunotherapy. Expert Opin Ther Targets.
2020;24:945-951.
11. Murata Y, Kotani T, Ohnishi H, Matozaki T. The CD47-SIRPalpha signalling system: its physiological roles and therapeutic application. J
Biochem. 2014;155:335-3 44.
12. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-
Hodgkin lymphoma. Cell. 2010;142:699-713.
13. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-s ignal
regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA.
2012;109:6662-6 667.
14. Zhao XW, van Beek EM, Schornagel K, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for
antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA.
2011;108:18342-18347.
15. Sim J, Sockolosky JT, Sangalang E, et al. Discovery of high affinity,
pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPalpha. MAbs. 2019;11:1036-1052.
16. Ho CC, Guo N, Sockolosky JT, et al. "Velcro" engineering of high
affinity CD47 ectodomain as signal regulatory protein alpha
(SIRPalpha) antagonists that enhance antibody-dependent cellular
phagocytosis. J Biol Chem. 2015;290:12650-12663.
17. Ring NG, Herndler-Brandstetter D, Weiskopf K, et al. Anti-
SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci USA. 2017;114:E1057
8-E10585.
18. Murata Y, Tanaka D, Hazama D, et al. Anti-human SIRPalpha
antibody is a new tool for cancer immunotherapy. Cancer Sci.
2018;109:1300-1308.
19. Yanagita T, Murata Y, Tanaka D, et al. Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight.
2017;2:e89140.
20. Alvey CM, Spinler KR, Irianto J, et al. SIRPA-inhibited, marrow-
derived macrophages engorge, accumulate, and differentiate in
13497006, 2021, 8, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.14971 by Kyushu University, Wiley Online Library on [05/11/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
3027
KOGA et al.
21. 22. 23. 24. 25. 26. 27. 28. 29. 3 0. 31. 32. 33. 3 4. 35. antibody-targeted regression of solid tumors. Curr Biol. 2017;27:2065-
2077.e6.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil
versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann
Surg Oncol. 2012;19:68-74.
Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study
of cisplatin and 5-fluorouracil with concurrent radiotherapy in
advanced squamous cell carcinoma of the esophagus: a Japan
Esophageal Oncology Group (JEOG)/Japan Clinical Oncology
Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615-619.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or
with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-0 48): a randomised, open-label, phase 3 study.
Lancet (London, England). 2019;394:1915-1928.
Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and
the approval of pembrolizumab for treatment of gastric cancer. Arch
Pathol Lab Med. 2019;143:330-337.
Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated
by the miR-133a tumor suppressor is a novel prognostic marker in
esophageal squamous cell carcinoma. Oncol Rep. 2012;28:465-472.
Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.
Cancer Res. 2011;71:1374-1384.
Goto H, Kojima Y, Matsuda K, et al. Efficacy of anti-CD47 antibody-
mediated phagocytosis with macrophages against primary effusion
lymphoma. Eur J Cancer. 2014;50:1836-1846.
Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized
anti-CD47 antibody with anti-c ancer therapeutic potential. PLoS
One. 2015;10:e0137345.
Zhang X, Fan J, Wang S, et al. Targeting CD47 and autophagy
elicited enhanced antitumor effects in non-small cell lung cancer.
Cancer Immunol Res. 2017;5:363-375.
Petrova PS, Viller NN, Wong M, et al. TTI-621 (SIRPαFc): a CD47-
blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res.
2017;23:1068-1079.
Russ A, Hua AB, Montfort WR, et al. Blocking "don't eat me" signal
of CD47-SIRPα in hematological malignancies, an in-depth review.
Blood Rev. 2018;32:480-489.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49-61.
Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-
associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7:e50946.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage
polarization: tumor-associated macrophages as a paradigm
for polarized M2 mononuclear phagocytes. Trends Immunol.
2002;23:549-555.
KOGA et al.
36. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated
macrophages are a distinct M2 polarised population promoting
tumour progression: potential targets of anti-c ancer therapy. Eur J
Cancer. 2006;42:717-727.
37. Miyashita T, Tajima H, Shah FA, et al. Impact of inflammation-
metaplasia-adenocarcinoma sequence and inflammatory microenvironment in esophageal carcinogenesis using surgical rat models.
Ann Surg Oncol. 2014;21:2012-2019.
38. Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated
macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci.
2013;104:1112-1119.
39. Chen YP, Kim HJ, Wu H, et al. SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. Blood Cancer J.
2019;9:84.
4 0. Pan YF, Tan YX, Wang M, et al. Signal regulatory protein alpha
is associated with tumor-polarized macrophages phenotype
switch and plays a pivotal role in tumor progression. Hepatology.
2013;58:680-691.
41. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by
tumour-associated macrophages inhibits phagocytosis and tumour
immunity. Nature. 2017;545:495-499.
42. Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW.
Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018;6:
1260-1273.
43. Papalampros A, Vailas M, Ntostoglou K, et al. Unique spatial immune profiling in pancreatic ductal adenocarcinoma with enrichment of exhausted and senescent T cells and diffused CD47-SIRPα
expression. Cancers. 2020;12:1825.
4 4. Liu B, Guo H, Xu J, et al. Elimination of tumor by CD47/PD-L1 dual-
targeting fusion protein that engages innate and adaptive immune
responses. MAbs. 2018;10:315-324.
45. Sockolosky JT, Dougan M, Ingram JR, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Proc Natl Acad Sci USA. 2016;113:E2646-E2654.
46. Liu X, Liu L, Ren Z, et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep.
2018;24:2101-2111.
S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Koga N, Hu Q, Sakai A, et al. Clinical
significance of signal regulatory protein alpha (SIRPα)
expression in esophageal squamous cell carcinoma. Cancer
Sci. 2021;112:3018–3028. https://doi.org/10.1111/cas.14971
13497006, 2021, 8, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cas.14971 by Kyushu University, Wiley Online Library on [05/11/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
3028 ...
論文の公開元へ
